Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of DCDS4501A alone and with rituximab in relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia
NL-OMON39626Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Sep 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of polatuzumab vedotin in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Genentech. Started Sep 2012; status: active, not recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON39626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39626.